Skip to Content
Looking to save on your medications?  Find out how 

3 Interactions found for:

dicyclomine
Interactions Summary
  • 2 Major
  • 1 Moderate
  • 0 Minor
  • dicyclomine

Drug Interactions

A total of 223 medications are known to interact with dicyclomine. Add another medication to view potential interactions with this medication.

Drug and Food Interactions

Moderate
Dicyclomine + Food

The following applies to the ingredients: Dicyclomine

GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.

MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.

References

  1. Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12

Drug and Pregnancy Interactions

The following applies to the ingredients: Dicyclomine

This drug should be used during pregnancy only if clearly needed.

US FDA pregnancy category:
-Oral capsules, tablets, and IM injection: B
-Oral solution: Not assigned

Risk summary: No data are available on the use of this drug in pregnant women to inform a drug-related risk.

Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

References

  1. Golden SM, Perman KI "Bilateral clinical anophthalmia: drugs as potential factors." South Med J 73 (1980): 1404-7
  2. Morelock S, Hingson R, Kayne H, Dooling E, Zuckerman B, Day N, Alpert JJ, Flowerdew G "Bendectin and fetal development. A study of Boston City Hospital." Am J Obstet Gynecol 142 (1982): 209-13
  3. Shapiro S, Heinonen OP, Siskind V, Kaufman DW, Monson RR, Slone D "Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score." Am J Obstet Gynecol 128 (1977): 480-5
  4. Miklovich L, van den Berg BJ "An evaluation of the teratogenicity of certain antinauseant drugs." Am J Obstet Gynecol 125 (1976): 244-8
  5. Wheatley D "Treatment of pregnancy sickness." Br J Obstet Gynaecol 84 (1977): 444-7
  6. Harron DW, Griffiths K, Shanks RG "Debendox and congenital malformations in Northern Ireland." Br Med J 281 (1980): 1379-81
  7. DonnaiD, Harris R "Unusual fetal malformations after antiemetics in early pregnancy." Br Med J 1 (1978): 691-2
  8. Fleming DM, Knox JD, Crombie DL "Debendox in early pregnancy and fetal malformation." Br Med J (Clin Res Ed) 283 (1981): 99-101
  9. Williams J, Watkins-Jones R "Dicyclomine: worrying symptoms associated with its use in some small babies." Br Med J (Clin Res Ed) 288 (1984): 901
  10. Patterson DC "Congenital deformities associated with Benedectin." Can Med Assoc J 116 (1977): 1348
  11. Cordero JF, Oakley GP Jr "Drug exposure during pregnancy: some epidemiologic considerations." Clin Obstet Gynecol 26 (1983): 418-28
  12. Huff PS "Safety of drug therapy for nausea and vomiting of pregnancy." J Fam Pract 11 (1980): 969-70
  13. Correy JF, Newman NM "Debendox withdrawn." Med J Aust 140 (1984): 796-7
  14. Altman PM "Debendox withdrawn." Med J Aust 140 (1984): 119
  15. Correy JF, Newman NM "Debendox and limb reduction deformities." Med J Aust 1 (1981): 417-8
  16. Gibson GT, Colley DP, McMichael AJ, Hartshorne JM "Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors: an ongoing prospective study." Med J Aust 1 (1981): 410-4
  17. Sheffield LJ, Batagol R "The creation of therapeutic orphans--or, what have we learnt from the Debendox fiasco?" Med J Aust 143 (1985): 143-7
  18. Maling TJ "Debendox: a statement from the New Zealand Adverse Drug Reactions Committee." N Z Med J 97 (1984): 203-4
  19. Harris R, Donnai D "Debendox and the media." Br Med J 280 (1980): 480-1
  20. Mellor S "Fetal malformation after debendox treatment in early pregnancy." Br Med J 1 (1978): 1055
  21. Smithells RW, Sheppard S "Fetal malformation after debendox treatment in early pregnancy." Br Med J 1 (1978): 1055-6
  22. Dickson JH "Congenital deformities associated with bendectin." Can Med Assoc J 117 (1977): 721-2
  23. Congenital Abnormalities Sub-Committee of the Australian Drug Evaluation Committtee "Debendox in pregnancy." Med J Aust 1 (1980): 197
  24. Gordon I "Debendox." Med J Aust 144 (1986): 51-2
  25. Mitchell AA "Debendox." Med J Aust 144 (1986): 52
  26. "Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals (2002):
  27. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  28. "Product Information. Dicyclomine Hydrochloride (dicyclomine)." Teva Pharmaceuticals USA (2024):
  29. "Product Information. Dicyclomine Hydrochloride (dicyclomine)." Hikma Pharmaceuticals USA Inc. (2023):

Drug and Breastfeeding Interactions

The following applies to the ingredients: Dicyclomine

Use should be avoided.

Excreted into human milk: Yes
Excreted into animal milk: Data not available

Comments: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

A single case has been reported of a breast-fed 12 day old infant who developed apnea whose mother was receiving dicyclomine. A causal relationship between dicyclomine and apnea could not be confirmed. Similar adverse reactions have occurred with direct administration of dicyclomine to infants.

References

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation." Baltimore, MD: Williams & Wilkins (1998):
  2. "Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals (2002):
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Therapeutic Duplication Warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Switch to: Consumer Interactions

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.